Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

A 'Disease Severity Index' to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia.

Ferreira D, Falahati F, Linden C, Buckley RF, Ellis KA, Savage G, Villemagne VL, Rowe CC, Ames D, Simmons A, Westman E.

Sci Rep. 2017 Mar 13;7:44368. doi: 10.1038/srep44368.

2.

Comparisons of neurodegeneration over time between healthy ageing and Alzheimer's disease cohorts via Bayesian inference.

Cespedes MI, Fripp J, McGree JM, Drovandi CC, Mengersen K, Doecke JD.

BMJ Open. 2017 Feb 7;7(2):e012174. doi: 10.1136/bmjopen-2016-012174.

3.

A Multi-Cohort Study of ApoE ɛ4 and Amyloid-β Effects on the Hippocampus in Alzheimer's Disease.

Khan W, Giampietro V, Banaschewski T, Barker GJ, Bokde AL, Büchel C, Conrod P, Flor H, Frouin V, Garavan H, Gowland P, Heinz A, Ittermann B, Lemaître H, Nees F, Paus T, Pausova Z, Rietschel M, Smolka MN, Ströhle A, Gallinat J, Vellas B, Soininen H, Kloszewska I, Tsolaki M, Mecocci P, Spenger C, Villemagne VL, Masters CL, Muehlboeck JS, Bäckman L, Fratiglioni L, Kalpouzos G, Wahlund LO, Schumann G, Lovestone S, Williams SC, Westman E, Simmons A; Alzheimer–s Disease Neuroimaging Initiative.; AddNeuroMed Consortium, Australian, Imaging, Biomarkers, and Lifestyle Study Research Group.; IMAGEN consortium..

J Alzheimers Dis. 2017;56(3):1159-1174. doi: 10.3233/JAD-161097.

4.

Usefulness of DNA Methylation Levels in COASY and SPINT1 Gene Promoter Regions as Biomarkers in Diagnosis of Alzheimer's Disease and Amnestic Mild Cognitive Impairment.

Kobayashi N, Shinagawa S, Nagata T, Shimada K, Shibata N, Ohnuma T, Kasanuki K, Arai H, Yamada H, Nakayama K, Kondo K.

PLoS One. 2016 Dec 19;11(12):e0168816. doi: 10.1371/journal.pone.0168816. eCollection 2016 Dec 19.

5.

Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review.

Bemelmans SA, Tromp K, Bunnik EM, Milne RJ, Badger S, Brayne C, Schermer MH, Richard E.

Alzheimers Res Ther. 2016 Nov 10;8(1):46.

6.

Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ.

Neurotherapeutics. 2017 Jan;14(1):35-53. doi: 10.1007/s13311-016-0481-z. Review.

PMID:
27738903
7.

Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information.

Insel PS, Palmqvist S, Mackin RS, Nosheny RL, Hansson O, Weiner MW, Mattsson N.

Alzheimers Dement (Amst). 2016 Aug 3;4:76-84. eCollection 2016 Aug 3.

8.

Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, Gunter JL, Senjem ML, Jones DT, Kantarci K, Machulda MM, Mielke MM, Roberts RO, Vemuri P, Reyes DA, Petersen RC.

Alzheimers Dement. 2017 Mar;13(3):205-216. doi: 10.1016/j.jalz.2016.08.005. Epub 2016 Sep 30.

9.
10.

qPR: An adaptive partial-report procedure based on Bayesian inference.

Baek J, Lesmes LA, Lu ZL.

J Vis. 2016 Aug 1;16(10):25. doi: 10.1167/16.10.25.

11.

Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals.

Mormino EC, Papp KV, Rentz DM, Schultz AP, LaPoint M, Amariglio R, Hanseeuw B, Marshall GA, Hedden T, Johnson KA, Sperling RA.

JAMA Neurol. 2016 Oct 1;73(10):1185-1191. doi: 10.1001/jamaneurol.2016.2237.

PMID:
27548655
12.
13.

A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease.

Buckley RF, Villemagne VL, Masters CL, Ellis KA, Rowe CC, Johnson K, Sperling R, Amariglio R.

J Mol Neurosci. 2016 Nov;60(3):354-361. Epub 2016 Aug 11. Review.

14.

Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores.

Arbor SC, LaFontaine M, Cumbay M.

Yale J Biol Med. 2016 Mar 24;89(1):5-21. eCollection 2016 Mar 24. Review.

15.

Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score.

Lim YY, Snyder PJ, Pietrzak RH, Ukiqi A, Villemagne VL, Ames D, Salvado O, Bourgeat P, Martins RN, Masters CL, Rowe CC, Maruff P.

Alzheimers Dement (Amst). 2015 Dec 12;2:19-26. doi: 10.1016/j.dadm.2015.11.003. eCollection 2015 Dec 12.

16.

Blood protein predictors of brain amyloid for enrichment in clinical trials?

Ashton NJ, Kiddle SJ, Graf J, Ward M, Baird AL, Hye A, Westwood S, Wong KV, Dobson RJ, Rabinovici GD, Miller BL, Rosen HJ, Torres A, Zhang Z, Thurfjell L, Covin A, Hehir CT, Baker D, Bazenet C, Lovestone S; AIBL Research Group..

Alzheimers Dement (Amst). 2015 Mar 29;1(1):48-60. doi: 10.1016/j.dadm.2014.11.005. eCollection 2015 Mar 29.

17.

Genome instability in Alzheimer disease.

Hou Y, Song H, Croteau DL, Akbari M, Bohr VA.

Mech Ageing Dev. 2017 Jan;161(Pt A):83-94. doi: 10.1016/j.mad.2016.04.005. Epub 2016 Apr 20.

PMID:
27105872
18.

The Relationship between Sleep Quality and Brain Amyloid Burden.

Brown BM, Rainey-Smith SR, Villemagne VL, Weinborn M, Bucks RS, Sohrabi HR, Laws SM, Taddei K, Macaulay SL, Ames D, Fowler C, Maruff P, Masters CL, Rowe CC, Martins RN; AIBL Research Group..

Sleep. 2016 May 1;39(5):1063-8. doi: 10.5665/sleep.5756.

19.

Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.

Soldan A, Pettigrew C, Cai Q, Wang MC, Moghekar AR, O'Brien RJ, Selnes OA, Albert MS; BIOCARD Research Team..

JAMA Neurol. 2016 Jun 1;73(6):698-705. doi: 10.1001/jamaneurol.2016.0194.

PMID:
27064267
20.

In Vivo Amyloid-β Imaging in the APPPS1-21 Transgenic Mouse Model with a (89)Zr-Labeled Monoclonal Antibody.

Waldron AM, Fissers J, Van Eetveldt A, Van Broeck B, Mercken M, Pemberton DJ, Van Der Veken P, Augustyns K, Joossens J, Stroobants S, Dedeurwaerdere S, Wyffels L, Staelens S.

Front Aging Neurosci. 2016 Mar 31;8:67. doi: 10.3389/fnagi.2016.00067. eCollection 2016 Mar 31.

Supplemental Content

Support Center